Top

BMC Psychiatry

Published in:

Open Access 01-12-2021 | Schizophrenia | Study protocol

Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial

Authors: Jesper Østrup Rasmussen, Poul Jennum, Kristian Linnet, Birte Y. Glenthøj, Lone Baandrup

Published in: BMC Psychiatry | Issue 1/2021

Abstract

Background

Cannabis use is an important risk factor for development of psychosis and further transition to schizophrenia. The prevalence of patients with psychosis and comorbid cannabis use (dual diagnosis) is rising with no approved specialized pharmacological treatment option. Cannabidiol, a constituent of the Cannabis sativa plant, has potential both as an antipsychotic and as a cannabis substituting agent.

The aim of this study is to evaluate the efficacy of cannabidiol versus a first-choice second-generation antipsychotic (risperidone) in patients with early psychosis and comorbid cannabis use.

Methods

The study is a phase II randomized, double-blinded, parallel-group, active-comparator clinical trial. We plan to include 130 patients aged between 18 and 64 years with a recent diagnosis of psychosis, comorbid cannabis use, and currently not treated with antipsychotics. The participants will be randomized to seven weeks of treatment with either cannabidiol 600 mg (300 mg BID) or risperidone 4 mg (2 mg BID). Participants will undergo clinical assessment after 1, 3, 5 and 7 weeks, telephone assessment the weeks in between, and a safety visit two weeks after end of treatment. The primary outcomes are cessation of cannabis use (self-reported) and psychotic symptom severity. The secondary outcomes include frequency and quantity of cannabis use, global illness severity, psychosocial functioning, subjective well-being, cognition, sleep, circadian rhythmicity, and metabolomics.

Discussion

The results of this trial can potentially contribute with a new treatment paradigm for patients suffering from dual diagnosis.

Trial registration

ClinicalTrials.gov, NCT04105231, registered April 23rd, 2021

Murray RM, Englund A, Abi-Dargham A, Lewis DA, Di Forti M, Davies C, et al. Cannabis-associated psychosis: neural substrate and clinical impact. Neuropharmacology. 2017;124:89–104. https://doi.org/10.1016/j.neuropharm.2017.06.018.CrossRefPubMed

Seddon JL, Birchwood M, Copello A, Everard L, Jones PB, Fowler D, et al. Cannabis use is associated with increased psychotic symptoms and poorer psychosocial functioning in first-episode psychosis: a report from the UK national EDEN study. Schizophr Bull. 2016;42(3):619–25. https://doi.org/10.1093/schbul/sbv154.CrossRefPubMed

Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Preference Adherence. 2017;Volume 11:449–68. https://doi.org/10.2147/PPA.S124658.CrossRef

Goff DC. The pharmacologic treatment of schizophrenia - 2021. JAMA. 2021;325(2). https://doi.org/10.1001/jama.2020.19048.

Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427–36. https://doi.org/10.1016/S2215-0366(19)30048-3.CrossRefPubMedPubMedCentral

Murrie B, Lappin J, Large M, Sara G. Transition of substance-induced, brief, and atypical psychoses to schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2020;46(3):505–16. https://doi.org/10.1093/schbul/sbz102.CrossRefPubMed

Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, et al. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open. 2016;6(3):e009888. https://doi.org/10.1136/bmjopen-2015-009888.CrossRefPubMedPubMedCentral

Krause M, Huhn M, Schneider-Thoma J, Bighelli I, Gutsmiedl K, Leucht S. Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2019;29(1):32–45. https://doi.org/10.1016/j.euroneuro.2018.11.1105.CrossRefPubMed

Hunt GE, Siegfried N, Morley K, Brooke-Sumner C, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2019;12(12):CD001088. https://doi.org/10.1002/14651858.CD001088.pub4.

10.

Crockford D, Addington D. Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatr. 2017;62(9):624–34. https://doi.org/10.1177/0706743717720196.CrossRef

11.

Schubart CD, Sommer IEC, Fusar-Poli P, de Witte L, Kahn RS, Boks MPM. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014;24(1):51–64. https://doi.org/10.1016/j.euroneuro.2013.11.002.CrossRefPubMed

12.

Ryan D, Drysdale AJ, Pertwee RG, Platt B. Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. Eur J Neurosci. 2007;25(7):2093–102. https://doi.org/10.1111/j.1460-9568.2007.05448.x.CrossRefPubMed

13.

Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, et al. Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism. Brain Res. 2008;1188:157–64. https://doi.org/10.1016/j.brainres.2007.09.090.CrossRefPubMed

14.

Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro. Br J Pharmacol. 2007;150(5):613–23. https://doi.org/10.1038/sj.bjp.0707133.CrossRefPubMedPubMedCentral

15.

Leweke FM, Mueller JK, Lange B, Rohleder C. Therapeutic potential of cannabinoids in psychosis. Biol Psychiatry. 2016;79(7):604–12. https://doi.org/10.1016/j.biopsych.2015.11.018.CrossRefPubMed

16.

Fakhoury M. Could cannabidiol be used as an alternative to antipsychotics? J Psychiatr Res. 2016;80:14–21. https://doi.org/10.1016/j.jpsychires.2016.05.013.CrossRefPubMed

17.

Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(3):e94. https://doi.org/10.1038/tp.2012.15.CrossRefPubMedPubMedCentral

18.

Lee JLC, Bertoglio LJ, Guimarães FS, Stevenson CW. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol. 2017;174(19):3242–56. https://doi.org/10.1111/bph.13724.CrossRefPubMedPubMedCentral

19.

Moltke J, Hindocha C. Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res. 2021;3(1):5. https://doi.org/10.1186/s42238-021-00061-5.

20.

Chemerinski E, Ho BC, Flaum M, Arndt S, Fleming F, Andreasen NC. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Compr Psychiatry. 2002;43(5):393–6. https://doi.org/10.1053/comp.2002.34627.CrossRefPubMed

21.

Hahn B. The potential of Cannabidiol treatment for Cannabis users with recent-onset psychosis. Schizophr Bull. 2018;44(1):46–53. https://doi.org/10.1093/schbul/sbx105.CrossRefPubMed

22.

Miyamoto S, Fredrik Jarskog L, Wolfgang Fleischhacker W. New therapeutic approaches for treatment-resistant schizophrenia: a look to the future. J Psychiatr Res. 2014;58:1–6. https://doi.org/10.1016/j.jpsychires.2014.07.001.CrossRefPubMed

23.

Broyd SJ, Van Hell HH, Beale C, Yücel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition - a systematic review. Biol Psychiatry. 2016;79(7):557–67. https://doi.org/10.1016/j.biopsych.2015.12.002.CrossRefPubMed

24.

Colizzi M, Bhattacharyya S. Does Cannabis composition matter? Differential effects of Delta-9-tetrahydrocannabinol and Cannabidiol on human cognition. Curr Addict Rep. 2017;4(2):62–74. https://doi.org/10.1007/s40429-017-0142-2.CrossRefPubMedPubMedCentral

25.

McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatr. 2018;175(3):225–31. https://doi.org/10.1176/appi.ajp.2017.17030325.CrossRefPubMed

26.

Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020;7(10):865–74. https://doi.org/10.1016/s2215-0366(20)30290-x.CrossRefPubMedPubMedCentral

27.

Lintzeris N, Bhardwaj A, Mills L, Dunlop A, Copeland J, McGregor I, Bruno R, Gugusheff J, Phung N, Montebello M, Chan T, Kirby A, Hall M, Jefferies M, Luksza J, Shanahan M, Kevin R, Allsop D. Agonist Replacement for Cannabis Dependence (ARCD) study group. Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. JAMA Intern Med. 2019;179(9):1242–53. https://doi.org/10.1001/jamainternmed.2019.1993.

28.

World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. https://doi.org/10.1001/jama.2013.281053.

29.

Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RHC, et al. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers’ blood on per se drugged driving laws. Clin Chem. 2013;59(3):519–26. https://doi.org/10.1373/clinchem.2012.195503.CrossRefPubMedPubMedCentral

30.

Mørland J, Bramness JG. Δ9-tetrahydrocannabinol (THC) is present in the body between smoking sessions in occasional non-daily cannabis users. Forensic Sci Int. 2020;309:110188. https://doi.org/10.1016/j.forsciint.2020.110188.CrossRefPubMed

31.

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76. https://doi.org/10.1093/schbul/13.2.261.CrossRefPubMed

32.

Leucht S, Kissling W, Davis JM. The PANSS should be rescaled. Schizophr Bull. 2010;36(3):461–2. https://doi.org/10.1093/schbul/sbq016.CrossRefPubMedPubMedCentral

33.

Sobell LC, Sobell MB. Timeline Follow-Back. In: Litten RZ, Allen JP. (eds). Measuring Alcohol Consumption. Totowa: Humana Press; 1992. https://doi.org/10.1007/978-1-4612-0357-5_3.

34.

Van Laar M, Frijns T, Trautmann F, Lombi L. Sizing the cannabis market: a demand-side and user-specific approach in seven European countries. Curr Drug Abuse Rev. 2013;6(2):152–64. https://doi.org/10.2174/1874473706666131205152835.CrossRefPubMed

35.

Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatr. 2005;162(3):441–9. https://doi.org/10.1176/appi.ajp.162.3.441.CrossRefPubMed

36.

Guy W. Clinical Global Impressions, ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ. No. ADM 76-338). Rockville: National Institute of Mental Health; 1976:218–22.

37.

Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social funtioning. Acta Psychiatrica Scandinavica. 2000;101(4):323–9. https://doi.org/10.1034/j.1600-0447.2000.101004323.x.CrossRefPubMed

38.

Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2-3):283–97. https://doi.org/10.1016/j.schres.2003.09.011.CrossRefPubMed

39.

Vothknecht S, Schoevers RA, De Haan L. Subjective well-being in schizophrenia as measured with the subjective well-being under neuroleptic treatment scale: a review. Aust N Z J Psychiatry. 2011;45(3):182–92. https://doi.org/10.3109/00048674.2010.545984.CrossRefPubMed

40.

Walia HK, Mehra R. Practical aspects of actigraphy and approaches in clinical and research domains. Handb Clin Neurol. 2019;160:371–9. https://doi.org/10.1016/B978-0-444-64032-1.00024-2.

41.

Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. https://doi.org/10.1016/0165-1781(89)90047-4.CrossRef

42.

Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006;31(10):2318–25. https://doi.org/10.1038/sj.npp.1301147.CrossRefPubMed

43.

Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62(12):1305–12. https://doi.org/10.1001/archpsyc.62.12.1305.CrossRefPubMed

44.

Freeman TP, Craft S, Wilson J, Stylianou S, ElSohly M, Di Forti M, et al. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction. 2021;116(5):1000–10. https://doi.org/10.1111/add.15253.CrossRefPubMed

45.

Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction. 2017;112(12):2167–77. https://doi.org/10.1111/add.13886.CrossRefPubMedPubMedCentral

Title: Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial
Authors: Jesper Østrup Rasmussen
Poul Jennum
Kristian Linnet
Birte Y. Glenthøj
Lone Baandrup
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Schizophrenia
Antipsychotics
Antipsychotics
Risperidone
Published in: BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-021-03395-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial

Abstract

Background

Methods

Discussion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Anhedonia difference between major depressive disorder and bipolar disorder II

Atypical Charles Bonnet syndrome secondary to frontal meningioma: a case report

The experiences and strategies of parents’ of adults with anorexia nervosa or bulimia nervosa: a qualitative study

Physical activity, sedentary behaviour and smoking status among psychiatric patients in Singapore – a cross-sectional study

Elevated activity of superoxide dismutase in male late-life schizophrenia and its correlation with clinical symptoms and cognitive deficits

Measuring diagnostic heterogeneity using text-mining of the lived experiences of patients